521 results on '"Braunwald, Eugene"'
Search Results
2. Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial
3. Cardiology: A Century of Progress
4. Abstract 18200: Prognostic Importance of Serial NT-proBNP Measurements Following High-Risk Mi: The PARADISE-MI Trial
5. Abstract 14750: Performance of a Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of ASCVD: An Analysis of 60k Patients From 6 TIMI Randomized Trials
6. Abstract 14399: Development of Heart Failure in High-Risk Post-Myocardial Infarction Patients: An Analysis of the Paradise-MI Trial
7. Abstract 12701: Safety and Tolerability of Angiotensin Receptor Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Drug Initiation Setting: A Subgroup Analysis of the PARADISE-MI Trial
8. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
9. Abstract 12228: Development of a Novel Polygenic Risk Score to Predict Risk of Aortic Stenosis Events
10. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial
11. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease
12. Abstract 16185: Biomarker-based Heart Failure Risk Stratification in Patients With Atherosclerotic Cardiovascular Disease: Observations From HPS-3/TIMI-55-REVEAL
13. Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease
14. Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes
15. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
16. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
17. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial
18. Impact of ADCY9 Genotype on Response to Anacetrapib
19. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
20. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48
21. Glucose–Insulin–Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook
22. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial
23. Response by Bohula et al to Letters Regarding Article, “Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)”
24. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis
25. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
26. Abstract 17950: High-Dose Edoxaban Regimen versus Warfarin in Patients With Atrial Fibrillation and Established Coronary Artery Disease: Insights From the ENGAGE AF-TIMI 48 Trial
27. Abstract 17307: Biomarkers, Cardiovascular Outcomes and Effect of Ezetimibe After Acute Coronary Syndrome in the IMPROVE-IT Trial
28. Abstract 17194: High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure and a Preserved Ejection Fraction - Insights From the Heart Failure Network
29. Abstract 16613: Serial High-Sensitivity Troponin T and Cardiovascular Outcomes in Patients in the IMPROVE-IT Trial
30. Abstract 15480: The Efficacy and Safety of More Potent Antiplatelet Therapy With Vorapaxar in Patients With Impaired Renal Function: Insights From the TRA 2P-TIMI 50 Trial
31. Abstract 15134: Comparison of Events Across Definitions of Major Bleeding in the Engage AF-TIMI 48 Trial
32. Abstract 11709: Klotho, Fibroblast Growth Factor-23, and the Renin-Angiotensin System - An Analysis From the PEACE Trial
33. Abstract 9153: Predictive and Protective Factors of Early, Late, and Very Late Stent Thrombosis in Acute Coronary Syndrome Patients Undergoing Coronary Stent Implantation: Findings from the Atlas Acs 2-timi 51 Trial
34. Abstract 9396: Evaluation of the ABC Pathway for Comprehensive Management of Atrial Fibrillation in 20,933 Patients from the ENGAGE AF-TIMI 48 Trial
35. Abstract 9110: Use of a Genetic Risk Score to Predict Atrial Fibrillation in Patients With Cardiovascular Disease
36. Abstract 9393: A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease
37. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
38. Circulation: The Beat Goes On
39. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials
40. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
41. Aortic Stenosis
42. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus
43. Abstract 19694: Reduction in Non-hemorrhagic Stroke With Ezetimibe/Simvastatin Compared With Simvastatin Alone in the IMPROVE-IT Trial
44. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction
45. Limitation of Infarct Size and the Open Artery Hypothesis
46. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction
47. Response to Letter Regarding Article, “Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT”
48. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease
49. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack
50. Abstract 17338: Development of a TIMI Risk Score for Stable Ischemic Heart Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.